Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chen Glait-Santar has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Ron Ram

    BMT Unit, Tel Aviv Sourasky Medical Center and Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel

    5 shared publications
  • Sigi Kay

    Hematology Institution, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    5 shared publications
  • Odelia Amit

    BMT and Cellular Therapy Unit, Hematology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    4 shared publications
  • Ronit Gold

    Hematology Institution, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    4 shared publications
  • Chava Perry

    Hematology Institution, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    3 shared publications
  • David Hagin

    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center, Israel

    3 shared publications

Latest Publications

  • Open Access

    Diagnostically challenging Pro-B ALL followed by emergence of monocytic AML after successful CAR-T treatment

    by Chen Glait Santar, Ben-Zion Katz

    Introduction: Therapy-related acute myeloid leukemia (t-AML) is a recognized complication of leukemia-directed cytotoxic therapy. However, the emergence of therapy-related monocytic AML shortly after successful CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for relapsed Pro-B acute lymphoblastic leukemia (B-ALL) raises important questions regarding clonal evolution, lineage plasticity, and treatment-related leukemogenesis. Case Description: We describe a 73-year-old man diagnosed with Philadelphia chromosome-negative Pro-B ALL with hyperdiploidy/tetraploidy, whose initial presentation posed a diagnostic challenge due to expression of immature and partial myeloid-associated markers, initially suggesting minimally differentiated AML. Repeat immunophenotyping clarified the diagnosis as Pro-B ALL. The patient achieved complete remission with the GMALL Elderly protocol despite severe infectious and treatment-related complications. Following relapse during maintenance therapy, he received salvage treatment with inotuzumab ozogamicin followed by CD19-directed CAR-T therapy, achieving marrow remission. Five months later, he developed secondary monocytic AML with no immunophenotypic evidence of residual B-ALL. Conclusion: This case underscores the importance of precise immunophenotypic characterization in diagnostically ambiguous acute leukemias and illustrates the complex biologic evolution that may follow sequential chemotherapy and modern immunotherapeutic approaches, including the emergence of secondary myeloid neoplasms after CAR-T therapy.

  • Open Access

    Flow Cytometry‐Guided Diagnosis of Cortical T‐Lymphoblastic Lymphoma Presenting With a Massive Mediastinal Mass and Borderline Bone Marrow Involvement

    by Chen Glait‐Santar, Yakir Moshe, Itzhaki‐Alfia Ayelet, Ben‐Zion Katz

    Background: T‐cell lymphoblastic lymphoma (T‐LBL) and T‐cell acute lymphoblastic leukemia (T‐ALL) are considered a single biological entity, distinguished primarily by the extent of bone marrow infiltration. This distinction becomes diagnostically challenging in patients with borderline marrow blast counts and predominantly extramedullary disease, risking overclassification as leukemia. Methods: We describe a 57‐year‐old man who presented with dyspnea and a large mediastinal mass causing superior vena cava syndrome, with pleural and pericardial effusions. Diagnostic workup included complete blood count and biochemistry, imaging, fine‐needle aspiration, core biopsy, pleural fluid cytology, multiparameter flow cytometry of pleural fluid and bone marrow, immunohistochemistry, and cerebrospinal fluid analysis. Results: CBC and biochemistry were largely unremarkable aside from elevated LDH and CRP. Cytology and biopsy showed a diffuse blastoid lymphoid infiltrate. Pleural fluid flow cytometry identified an aberrant immature T‐cell population (cytoplasmic CD3+, CD1a+, CD2+, CD4+, CD5(dim)+, CD7+, CD8+, CD10+, TdT+; surface CD3−, CD34−, MPO−), confirming cortical T‐ALL/LBL and excluding B‐ and myeloid‐lineage differentiation. Bone marrow morphology suggested ~10% blasts, but flow cytometry detected only 3.8% CD34+ cells with a myeloid‐skewed, non‐T‐lymphoblastic phenotype, arguing against significant marrow involvement. The patient was classified as T‐LBL and treated per the GMALL protocol, achieving complete remission. Conclusion: Flow cytometry resolved a discrepancy between morphologic and immunophenotypic assessment of bone marrow involvement, preventing overclassification as T‐ALL. Multiparameter flow cytometry is essential for accurate lineage assignment and staging of precursor T‐lymphoid neoplasms in cytologic specimens and borderline marrow samples.

  • Flow cytometric detection of isolated central nervous system relapse in acute myeloid leukemia under FLT3-targeted therapy

    by Chen Glait Santar, Odelia Amit, Ben Zion Katz

    Central nervous system (CNS) relapse in acute myeloid leukemia (AML) is rare in adults and infrequently occurs as an isolated manifestation following allogeneic hematopoietic stem cell transplantation. We report a 68-year-old man with FLT3-ITD–mutated AML with monocytic differentiation who achieved sustained morphological and molecular remission following induction chemotherapy, consolidation, allogeneic transplantation, and FLT3 inhibitor maintenance therapy. Approximately 18 months after diagnosis, the patient developed isolated CNS relapse despite continued bone marrow remission and complete donor chimerism. Cerebrospinal fluid (CSF) flow cytometry identified leukemic blasts, and PCR detected FLT3-ITD, confirming CNS involvement. Following intrathecal chemotherapy, systemic therapy, gilteritinib treatment, and a second transplantation, the patient developed recurrent CNS disease with optic nerve involvement and vision loss. Notably, repeat CSF studies demonstrated persistent leukemic infiltration detectable by flow cytometry despite repeated negative FLT3-ITD PCR results, suggesting immunophenotypic–molecular discordance under FLT3-targeted therapy. This case highlights the CNS as a sanctuary site in AML and underscores the critical role of CSF flow cytometry in the diagnosis and monitoring of CNS relapse, particularly when molecular studies are negative. This case provides a valuable teaching point highlighting the limitations of relying on a single diagnostic method. Graphical Abstract

  • Open Access

    Blastic plasmacytoid dendritic cell neoplasm with atypical immunophenotype and concurrent BCL3-associated lymphoid clone

    by Chen Glait Santar, Lucille Hayman, Ben Zion Katz

    Blastic plasmacytoid dendritic cell (pDC) neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with significant diagnostic challenges, particularly when atypical immunophenotypic features overlap with mature pDC proliferation associated with myeloid neoplasms. We report a 76-year-old man with a history of chronic myelomonocytic leukemia presenting with extensive cutaneous lesions and a blast population expressing CD4, CD56, CD123, CD304 and cytoplasmic TCL1, but lacking CD303 and exhibiting aberrant CD117 and CD33 expression, creating a diagnostic gray zone. Optical genome mapping identified trisomy 12 and t(14;19) (p13.13; q32.12) involving the immunoglobulin heavy chain locus, a genomic profile associated with BCL3-driven B-cell lymphoproliferative disorders. Concurrent flow cytometry demonstrated a distinct clonal B-cell population, associated with overexpressed cyclin D1, consistent with mantle cell lymphoma, confirming a composite hematologic malignancy. To our knowledge this is the first report of BPDCN coexisting with a t(14;19)-associated lymphoid clone, highlighting the critical role of integrated immunophenotypic and genomic analysis in resolving diagnostic ambiguity and guiding targeted therapy.

  • Open Access

    Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion—A Phase 2, Prospective Interventional Study

    by Ron Ram, Odelia Amit, Chava Perry, Yair Herishanu, Irit Avivi, Nadav Sarid, Arie Apel, Meir Preis, Ariel Aviv, Shirly Shapira, et al.


  • Open Access

    The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy

    by Gil Fridberg, Galit Horn, Anat Globerson Levin, Dan Benisty, Sigi Kay, Chen Glait-Santar, Chava Perry, Ron Ram, Irit Avivi, Ben-Zion Katz

    Chimeric Antigen Receptor T-cell (CAR T) therapy has become the preferable treatment in relapsed/refractory diffuse large B-cell lymphomas (DLBCL) patients. Detection of CAR Ts in peripheral blood smear (PBS) is challenging due to insufficient data regarding their morphology and low sensitivity. The morphological evolution of CAR Ts along their production process, and in patients, was established by Full-Field Morphology (FFM), a novel digital microscopy approach that provides highly sensitive PBS analysis. At day 8 of production, 42.7 ± 10.8% of the CAR T transduced cells exhibited activated morphology compared with 9.3 ± 3.8% in untransduced cells. Moreover, engagement of transduced CAR Ts with target cells resulted in further morphological transformation into activated morphology (83 ± 5.6% of the cells). In patients, the average number of day 5 CAR Ts, and their sustained presence, were significantly higher in patients obtaining complete response. A high number of activated morphology CAR Ts at day 14 was associated with prolonged cytokine release storm. Overall, CAR Ts exhibited heterogeneous morphology, with the activated morphology attributed predominantly to transduced cells following engagement with target cells. Post-transfusion CAR T detection was associated with increased complete responses. FFM CAR T surveillance in PBS may serve as a simple inexpensive method to provide clinically relevant insights into this treatment modality.


  • Open Access

    Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes – A potential prognostic marker?

    by Reut Book, Jonathan Ben-Ezra, Chen Glait Santar, Sigi Kay, Galia Stemer, Howard S. Oster, Moshe Mittelman

    Background: Lymphoid aggregates (LA) are occasionally seen in bone marrow biopsies (BMB) of myelodysplastic syndromes (MDS) patients. Our aim was to evaluate their incidence and association with prognosis.Methods: We compared BMB reports of MDS patients treated at the Tel Aviv Sourasky Medical Center (2011-2018), and controls (2015-2017, normal BMB), and examined the charts of the MDS patients (LA+ and LA-). Categorical, normally and non-normally distributed continuous variables were compared using Fisher’s exact, independent t and Mann-Whitney tests respectively. Adjusted [age, gender, lymphocytes, white blood cells (WBC) and diabetes mellitus (DM)] Cox proportional hazard model examined survival at 12 and 24 months.Results: MDS patients (N=140) were older than controls (N=38; 74.1 vs 69.2 years, p=0.005); 34 MDS (24.3%) and 5 controls (13.2%) had LA+ (P=0.141). CD20/CD3 staining suggested LA polyclonality. MDS/LA+ (vs MDS/LA-) patients were younger, with a trend (not statistically significant) towards poor prognostic parameters: lower Hb, WBC, and platelets, higher LDH, BM cellularity, and IPSS-R score. The incidence of cardiovascular disease was similar, but MDS/LA+ had twice the incidence of DM (38.2% vs 19.0%, p=0.022). Similar trend for cancer (26.5% vs 14.3%, p=0.102). Twelve-month survival: 24/34 (70.6%) MDS/LA+; 88/106 (83.0%) MDS/LA- (p=0.140). This trend, seen in Kaplan-Meier curves, disappeared at 24 months. The hazard ratio for LA was 2.283 (p=0.055) for 12 months.Conclusion: These preliminary data suggest LA are relatively common (24%) in MDS BMB, and might indicate poor prognosis. This may reflect involvement of the immune system in MDS. Future studies will examine larger groups, to clarify the incidence, significance and the pathophysiology.


  • Open Access

    Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study

    by Ron Ram, Tal Freund, Tami Halperin, Ronen Ben-Ami, Odelia Amit, Yael Bar-On, Ofrat Beyar-Katz, Nili Eilaty, Ronit Gold, Sigi Kay, et al.